{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T02:33:16Z","timestamp":1791253996522,"version":"4.1.0"},"reference-count":28,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T00:00:00Z","timestamp":1650585600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["JGH Open"],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background and Aim<\/jats:title><jats:p>Immune checkpoint inhibitors (ICIs) can cause immune\u2010related adverse events in the liver. The risk of exacerbating liver injury is of concern in patients infected with hepatitis B virus (HBV) or hepatitis C virus (HCV), as immunotherapy can damage liver function because of the immune response against viral antigens. We assessed the feasibility of immunotherapy in HBV\u2010 or HCV\u2010infected patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This retrospective study included 266 patients with persistent or past HBV infection, 26 patients seropositive for anti\u2010HCV, and 820 patients with negative viral markers for HBV and HCV, who were treated with ICIs. ICI\u2010induced liver injury and changes in virological markers were analyzed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The occurrence rates of ICI\u2010induced liver injury in the HBsAg\u2010positive, anti\u2010HBc\u2010positive\/anti\u2010HBs\u2010positive, and anti\u2010HBc\u2010positive\/anti\u2010HBs\u2010negative groups were 12.5, 21.6, and 19.1%, respectively, which were comparable with those of the negative for HBV\u2010 and HCV\u2010related markers group (20.9%). The frequency of any grade ICI\u2010induced liver injury was different among the HCV RNA\u2010positive (3\/5; 60.0%), anti\u2010HCV\u2010positive\/HCV RNA\u2010negative (2\/21; 9.5%), and negative for HBV\u2010 and HCV\u2010related markers (171\/820; 20.9%) groups (<jats:italic>P<\/jats:italic>\u00a0=\u20090.045), with no significant difference in grade \u22652 ICI\u2010induced liver injury. In patients with persistent infection, neither serum HBV DNA, HBsAg, nor HCV RNA level changed significantly during ICI treatment. One of five treatment\u2010na\u00efve HCV\u2010infected patients required interruption of ICI treatment due to virus\u2010related liver injury.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Immunotherapy is feasible for most cancer patients with chronic HBV or HCV infection; however, liver function and virological markers should be carefully monitored in treatment\u2010na\u00efve patients, especially those with HCV infection, during ICI treatment.<\/jats:p><\/jats:sec>","DOI":"10.1002\/jgh3.12737","type":"journal-article","created":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T08:52:19Z","timestamp":1650617539000},"page":"309-316","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Feasibility of immunotherapy in cancer patients with persistent or past hepatitis B or C virus infection"],"prefix":"10.1002","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9486-850X","authenticated-orcid":false,"given":"Tasuku","family":"Nakabori","sequence":"first","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Oncology Osaka International Cancer Institute  Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaro","family":"Abe","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Oncology Osaka International Cancer Institute  Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sena","family":"Higashi","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Oncology Osaka International Cancer Institute  Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeru","family":"Hirao","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Oncology Osaka International Cancer Institute  Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuharu","family":"Kawamoto","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Oncology Osaka International Cancer Institute  Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Maeda","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Oncology Osaka International Cancer Institute  Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuma","family":"Daiku","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Oncology Osaka International Cancer Institute  Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makiko","family":"Urabe","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Oncology Osaka International Cancer Institute  Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yugo","family":"Kai","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Oncology Osaka International Cancer Institute  Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoji","family":"Takada","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Oncology Osaka International Cancer Institute  Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuo","family":"Yamai","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Oncology Osaka International Cancer Institute  Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7517-8960","authenticated-orcid":false,"given":"Kenji","family":"Ikezawa","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Oncology Osaka International Cancer Institute  Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Uehara","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Oncology Osaka International Cancer Institute  Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyoshi","family":"Ohkawa","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Oncology Osaka International Cancer Institute  Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,4,22]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3239"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30167-6"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1414428"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.07.032"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915745"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1816714"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411087"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-020-0897-9"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx225"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385"},{"key":"e_1_2_7_12_1","volume-title":"WHO Global Hepatitis Report, 2017","year":"2017"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.6437"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v22.i28.6469"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx502"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/5985131"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.47.1946"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2016.214"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-014-0033-1"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2020.02.013"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001072"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000001142"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.13504"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.12108"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.10.038"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2008.03.009"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.37.5.721"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.46.5831"},{"key":"e_1_2_7_29_1","first-page":"737389","article-title":"PD\u20101 Blockade in advanced melanoma in patients with hepatitis C and\/or HIV","volume":"2015","author":"Davar D","year":"2015","journal-title":"Case Rep. Oncol. Med."}],"container-title":["JGH Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jgh3.12737","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jgh3.12737","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jgh3.12737","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T02:19:23Z","timestamp":1692843563000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jgh3.12737"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,22]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["10.1002\/jgh3.12737"],"URL":"https:\/\/doi.org\/10.1002\/jgh3.12737","archive":["Portico"],"relation":{},"ISSN":["2397-9070","2397-9070"],"issn-type":[{"value":"2397-9070","type":"print"},{"value":"2397-9070","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,22]]},"assertion":[{"value":"2021-11-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-24","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}